Salimetrics Launches Saliva Testing with Industry-Leading SARS-CoV-2 IgG Antibody Multiplex Assay Used in Vaccine Clinical Trials
Share Article
Salimetrics now offers multiplex testing for antibodies against SARS-CoV-2 Nucleocapsid, Spike 1, and Spike 1 Receptor Binding Domain (RBD) using a single, easy-to-collect saliva sample. Researchers now have unparalleled access to saliva collection devices and COVID-19 antibody saliva testing on a robust and validated platform.
This effort provides an unparalleled opportunity to reliably test saliva samples for antibodies to a combination of three SARS-CoV-2 antigens (Spike, N, RBD) in the same, easy to collect sample.
CARLSBAD, Calif. (PRWEB)
March 16, 2021
The Salimetrics SalivaLab R&D Testing facility has recently adapted and completed a fit-for-purpose validation of the industry-leading multiplex for the detection of IgG antibodies to SARS-CoV-2 Nucleocapsid, Spike 1, and Spike 1 Receptor Binding Domain (RBD) in passive drool saliva samples. “Today, we are announcing the availability of the SARS-CoV-2 IgG Antibody Assay, 3-Plex at our Carlsbad Technology Center,” says Steve Granger, Ph.D., Salimetrics Chief Scientific Officer. “This effort provides an unparalleled opportunity to reliably test saliva samples for antibodies to a combination of three SARS-CoV-2 antigens in the same, easy to collect sample.” Using this assay, researchers can determine if a subject is uninfected (N, Spike and RBD negative), infected naturally (N, Spike and RBD positive), or vaccinated with one of the currently authorized vaccines (N negative, Spike and RBD positive).